Multiple myeloma (MM) is a B-cell malignancy characterised by a monoclonal expansion and accumulation of abnormal plasma cells in the bone marrow compartment. It is the second most common cancer of the blood and accounts for 1% of all malignancies.
Daratumumab is now being tested in clinical trials for newly diagnosed multiple myeloma patients in a four-drug combination vs. a three drug combination.
A new drug called venetoclax is showing impact when used with bortezomib and dexamethasone in heavily pretreated multiple myeloma patients.
What kind of treatment should myeloma patients consider at relapse? According to experts, that depends on the kind of relapse. Hear more from OncLive.